Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming September Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Second Quarter 2025 Financial Results on August 5
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Appoints Craig Thompson to Board of Directors
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports First Quarter 2025 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in The Citizens Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report First Quarter 2025 Financial Results on May 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Appoints Robert E. Hoffman to Board of Directors
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.